RenaBio Therapeutics, Inc. — Form D
RenaBio Therapeutics, Inc. of NATICK, MA, a company, filed a Form D exempt-offering notice with the SEC on 2025-02-26. The offering totals $4.2M, of which $250K was reported sold. Industry: Other Health Care.
Offering
- Filed: 2025-02-26
- Form: D
- Accession: 0002018021-25-000001
- Industry: Other Health Care
- Exemptions: 06b
- Total offering: $4.2M
- Amount sold: $250K
- Remaining: $3.9M
- Minimum investment: $5K
- Investors: 1
- Date of first sale: 2025-02-20
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-539252
Issuer
- Name: RenaBio Therapeutics, Inc.
- CIK: 0002018021
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2023
- Address: 22 STRATHMORE RD, #353, NATICK, MA, 01760
- Phone: (617) 721-0785
Officers, directors & promoters (8)
| Name | Role | Location |
|---|
| Hans Bitter | Director | Natick, MA |
| Jafari Mousa | Director | Natick, MA |
| Shengjun Ren | Director | Natick, MA |
| Zhenghua Wang | Director | Natick, MA |
| Yu (Zoe) Zhang | Director | Natick, MA |
| Shengjun Ren | Executive Officer | Natick, MA |
| Ren Shengjun | Director | NATICK, MA |
| Ren Shengjun | Executive Officer | NATICK, MA |
Other filings by this issuer (1)
More